NOVIAN Health Inc. Release: Walter Reed Bethesda Joins Novilase Clinical Trial

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO--(BUSINESS WIRE)--Novian Health, developer of Novilase® Breast Therapy, announced today that Walter Reed National Military Medical Center (Bethesda, Md.) is now a participating study site in the BR-002 Novilase Clinical Trial. The multi-center study is evaluating the effectiveness of Novilase Breast Therapy as an alternative to lumpectomy surgery for the treatment of small, early-stage breast cancers. Novian Health has already received FDA clearance for the use of Novilase Breast Therapy as an alternative to surgery for the treatment of benign breast tumors (fibroadenomas).

“Patients appreciate taking part in this clinical trial because they know they’re contributing to the possible improvement of breast cancer treatment in the future,” said Barbara Schwartzberg, M.D. “Because our enrollees have stepped forward, women someday may be able have their tumors treated as a convenient outpatient procedure, instead of an invasive surgery with anesthesia and a long recuperation.”

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC